Adagene Surges 11% to $2.50 as Analysts Boost Buy Rating & Target $7.00
Adagene’s stock jumps 11% to $2.50 as analysts maintain a buy rating, targeting $7.00 amid growing institutional interest in its NEObody & SAFEbody oncology platform.
2 minutes to read